Analyst Note
| Damien Conover, CFA |Sanofi reported solid first-quarter results, slightly above our expectations, but we don’t expect any major changes to our fair value estimate based on the minor outperformance. We continue to view the stock as undervalued with the market not fully appreciating the firm’s growth potential from currently marketed drugs and new pipeline products that also support the firm’s wide moat.